CA2584699C - Systeme et procede d'echantillonnage d'un analyte et analyse avec un hydrogel - Google Patents

Systeme et procede d'echantillonnage d'un analyte et analyse avec un hydrogel Download PDF

Info

Publication number: CA2584699C
Authority: CA; Canada
Prior art keywords: analyte; hydrogel; glucose; biological membrane; skin
Prior art date: 2004-10-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2584699A

Other languages

English (en)

Other versions

CA2584699A1 (fr

Inventor

Han Chuang

Shikha P. Barman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Echo Therapeutics Inc

Original Assignee

Echo Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-28

Filing date

2005-10-27

Publication date

2015-12-08

2005-09-13 Priority claimed from US11/223,960 external-priority patent/US20060094945A1/en

2005-10-27 Application filed by Echo Therapeutics Inc filed Critical Echo Therapeutics Inc

2006-05-11 Publication of CA2584699A1 publication Critical patent/CA2584699A1/fr

2015-12-08 Application granted granted Critical

2015-12-08 Publication of CA2584699C publication Critical patent/CA2584699C/fr

2025-10-27 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000017 hydrogel Substances 0.000 title claims abstract description 148
239000012491 analyte Substances 0.000 title claims abstract description 100
238000000034 method Methods 0.000 title abstract description 57
238000004458 analytical method Methods 0.000 title description 33
238000005070 sampling Methods 0.000 title description 13
210000001124 body fluid Anatomy 0.000 claims abstract description 89
239000010839 body fluid Substances 0.000 claims abstract description 89
238000012544 monitoring process Methods 0.000 claims abstract description 50
229920000671 polyethylene glycol diacrylate Polymers 0.000 claims abstract description 29
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 24
230000004907 flux Effects 0.000 claims abstract description 10
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 6
125000004386 diacrylate group Chemical group 0.000 claims abstract description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 119
239000008103 glucose Substances 0.000 claims description 119
235000019420 glucose oxidase Nutrition 0.000 claims description 63
239000004366 Glucose oxidase Substances 0.000 claims description 39
229940116332 glucose oxidase Drugs 0.000 claims description 39
108010015776 Glucose oxidase Proteins 0.000 claims description 38
108090000790 Enzymes Proteins 0.000 claims description 15
102000004190 Enzymes Human genes 0.000 claims description 15
229940088598 enzyme Drugs 0.000 claims description 15
229920000642 polymer Polymers 0.000 claims description 8
239000012528 membrane Substances 0.000 abstract description 121
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 43
229910052697 platinum Inorganic materials 0.000 abstract description 21
229920000936 Agarose Polymers 0.000 abstract description 17
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 abstract description 10
238000012937 correction Methods 0.000 abstract description 10
210000004379 membrane Anatomy 0.000 description 117
238000002604 ultrasonography Methods 0.000 description 81
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 78
239000000243 solution Substances 0.000 description 72
210000003491 skin Anatomy 0.000 description 71
239000000499 gel Substances 0.000 description 54
239000008280 blood Substances 0.000 description 38
210000004369 blood Anatomy 0.000 description 36
238000000605 extraction Methods 0.000 description 34
239000002357 osmotic agent Substances 0.000 description 31
239000010410 layer Substances 0.000 description 27
230000035699 permeability Effects 0.000 description 27
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
239000002953 phosphate buffered saline Substances 0.000 description 23
238000005259 measurement Methods 0.000 description 21
239000000853 adhesive Substances 0.000 description 19
230000001070 adhesive effect Effects 0.000 description 19
238000001514 detection method Methods 0.000 description 19
230000003204 osmotic effect Effects 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
239000003153 chemical reaction reagent Substances 0.000 description 15
229910052799 carbon Inorganic materials 0.000 description 14
230000008878 coupling Effects 0.000 description 14
238000010168 coupling process Methods 0.000 description 14
238000005859 coupling reaction Methods 0.000 description 14
230000004044 response Effects 0.000 description 14
230000035945 sensitivity Effects 0.000 description 14
239000012530 fluid Substances 0.000 description 13
239000000203 mixture Substances 0.000 description 13
239000011780 sodium chloride Substances 0.000 description 13
230000008901 benefit Effects 0.000 description 12
239000000126 substance Substances 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 10
238000002835 absorbance Methods 0.000 description 10
230000008859 change Effects 0.000 description 10
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
239000007788 liquid Substances 0.000 description 10
229920000557 Nafion® Polymers 0.000 description 9
230000000694 effects Effects 0.000 description 9
239000006260 foam Substances 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
239000000463 material Substances 0.000 description 9
230000000737 periodic effect Effects 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
239000011521 glass Substances 0.000 description 8
-1 interstitial fluid Substances 0.000 description 8
238000001069 Raman spectroscopy Methods 0.000 description 7
229920004890 Triton X-100 Polymers 0.000 description 7
239000013504 Triton X-100 Substances 0.000 description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
230000000975 bioactive effect Effects 0.000 description 7
125000002091 cationic group Chemical group 0.000 description 7
238000004949 mass spectrometry Methods 0.000 description 7
GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
238000004566 IR spectroscopy Methods 0.000 description 6
108090000854 Oxidoreductases Proteins 0.000 description 6
102000004316 Oxidoreductases Human genes 0.000 description 6
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
229940116269 uric acid Drugs 0.000 description 6
229920002873 Polyethylenimine Polymers 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000006227 byproduct Substances 0.000 description 5
239000000975 dye Substances 0.000 description 5
230000005684 electric field Effects 0.000 description 5
210000003722 extracellular fluid Anatomy 0.000 description 5
210000000245 forearm Anatomy 0.000 description 5
230000036571 hydration Effects 0.000 description 5
238000006703 hydration reaction Methods 0.000 description 5
239000004310 lactic acid Substances 0.000 description 5
235000014655 lactic acid Nutrition 0.000 description 5
238000000691 measurement method Methods 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
230000008823 permeabilization Effects 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
239000004033 plastic Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
230000000887 hydrating effect Effects 0.000 description 4
210000002751 lymph Anatomy 0.000 description 4
239000001103 potassium chloride Substances 0.000 description 4
235000011164 potassium chloride Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000037067 skin hydration Effects 0.000 description 4
238000000527 sonication Methods 0.000 description 4
241000894007 species Species 0.000 description 4
238000009010 Bradford assay Methods 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000000232 Lipid Bilayer Substances 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
108091006629 SLC13A2 Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
239000000227 bioadhesive Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
239000003599 detergent Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
230000002218 hypoglycaemic effect Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000011068 loading method Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
229960005489 paracetamol Drugs 0.000 description 3
229910000160 potassium phosphate Inorganic materials 0.000 description 3
235000011009 potassium phosphates Nutrition 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000000434 stratum corneum Anatomy 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
229920002554 vinyl polymer Polymers 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920001661 Chitosan Polymers 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
238000002679 ablation Methods 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
238000005842 biochemical reaction Methods 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000002322 conducting polymer Substances 0.000 description 2
229920001940 conductive polymer Polymers 0.000 description 2
239000004020 conductor Substances 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000002848 electrochemical method Methods 0.000 description 2
230000005672 electromagnetic field Effects 0.000 description 2
238000006056 electrooxidation reaction Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000003999 initiator Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000344 non-irritating Toxicity 0.000 description 2
229920000962 poly(amidoamine) Polymers 0.000 description 2
239000004584 polyacrylic acid Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000037380 skin damage Effects 0.000 description 2
238000002791 soaking Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000007614 solvation Methods 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000008961 swelling Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
BDGGUWSWAKGEGH-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride;hydrate Chemical compound O.[Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 BDGGUWSWAKGEGH-UHFFFAOYSA-M 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
BLXVTZPGEOGTGG-UHFFFAOYSA-N 2-[2-(4-nonylphenoxy)ethoxy]ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCO)C=C1 BLXVTZPGEOGTGG-UHFFFAOYSA-N 0.000 description 1
HCZBMENVWKFZDJ-UHFFFAOYSA-N 3-trimethylsilylpropane-1-thiol Chemical compound C[Si](C)(C)CCCS HCZBMENVWKFZDJ-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241001427367 Gardena Species 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
238000007605 air drying Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
229910021393 carbon nanotube Inorganic materials 0.000 description 1
239000002041 carbon nanotube Substances 0.000 description 1
239000003575 carbonaceous material Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
230000003749 cleanliness Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000015961 delipidation Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
229940111685 dibasic potassium phosphate Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000003618 dip coating Methods 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
238000004980 dosimetry Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
238000003411 electrode reaction Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229910021397 glassy carbon Inorganic materials 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
XCOHAFVJQZPUKF-UHFFFAOYSA-M octyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCC[N+](C)(C)C XCOHAFVJQZPUKF-UHFFFAOYSA-M 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
238000004313 potentiometry Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000007674 radiofrequency ablation Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000005060 rubber Substances 0.000 description 1
238000011012 sanitization Methods 0.000 description 1
238000007650 screen-printing Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
231100000245 skin permeability Toxicity 0.000 description 1
229940067741 sodium octyl sulfate Drugs 0.000 description 1
WFRKJMRGXGWHBM-UHFFFAOYSA-M sodium;octyl sulfate Chemical compound [Na+].CCCCCCCCOS([O-])(=O)=O WFRKJMRGXGWHBM-UHFFFAOYSA-M 0.000 description 1
235000011067 sorbitan monolaureate Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000012085 test solution Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
238000004383 yellowing Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150061—Means for enhancing collection
- A61B5/150083—Means for enhancing collection by vibration, e.g. ultrasound
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150969—Low-profile devices which resemble patches or plasters, e.g. also allowing collection of blood samples for testing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15134—Bladeless capillary blood sampling devices, i.e. devices for perforating the skin in order to obtain a blood sample but not using a blade, needle, canula, or lancet, e.g. by laser perforation, suction or pressurized fluids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B2010/0003—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements including means for analysis by an unskilled person

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Surgery (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Hematology (AREA)
Dermatology (AREA)
Optics & Photonics (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA2584699A 2004-10-28 2005-10-27 Systeme et procede d'echantillonnage d'un analyte et analyse avec un hydrogel Expired - Fee Related CA2584699C (fr)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US97496304A	2004-10-28	2004-10-28
US10/974,963		2004-10-28
US20133405A	2005-08-11	2005-08-11
US11/201,334		2005-08-11
US11/223,971		2005-09-13
US11/223,960 US20060094945A1 (en)	2004-10-28	2005-09-13	System and method for analyte sampling and analysis
US11/223,971 US8224414B2 (en)	2004-10-28	2005-09-13	System and method for analyte sampling and analysis with hydrogel
US11/223,957 US20060094944A1 (en)	2004-10-28	2005-09-13	System and method for analyte sampling and analysis with error correction
PCT/US2005/038785 WO2006050032A2 (fr)	2004-10-28	2005-10-27	Systeme et procede d'echantillonnage d'un analyte et analyse avec un hydrogel

Publications (2)

Publication Number	Publication Date
CA2584699A1 CA2584699A1 (fr)	2006-05-11
CA2584699C true CA2584699C (fr)	2015-12-08

Family

ID=38441686

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2584699A Expired - Fee Related CA2584699C (fr)	2004-10-28	2005-10-27	Systeme et procede d'echantillonnage d'un analyte et analyse avec un hydrogel

Country Status (4)

Country	Link
EP (1)	EP1819283A4 (fr)
AU (1)	AU2005302584B2 (fr)
CA (1)	CA2584699C (fr)
WO (3)	WO2006050032A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090137888A9 (en) *	2001-04-27	2009-05-28	Berman Herbert L	System for monitoring of patients
EP1969365B1 (fr)	2005-12-27	2016-09-21	Ascensia Diabetes Care Holdings AG	Systeme de capteur electrochimique comprenant un substrat dote d'au moins une ouverture et procede de production de ce dernier
US20070202562A1 (en) *	2006-02-27	2007-08-30	Curry Kenneth M	Flux limiting membrane for intravenous amperometric biosensor
RU2444980C2 (ru) *	2007-03-07	2012-03-20	Эко Терапьютикс, Инк.	Трансдермальная система мониторинга аналита и способы детекции аналита
CN102105103B (zh) *	2008-07-31	2015-09-09	希森美康株式会社	活体内成分的测定方法,用于活体内成分测定的数据处理方法,活体内成分测定装置及收集部件
US9216188B2 (en)	2008-09-04	2015-12-22	The General Hospital Corporation	Hydrogels for vocal cord and soft tissue augmentation and repair
EP2376059A2 (fr) *	2008-11-25	2011-10-19	B.G. Negev Technologies and Applications Ltd.	Composition pharmaceutique et système pour la perméabilisation de membranes foetales
EP2208458A1 (fr) *	2009-01-14	2010-07-21	Roche Diagnostics GmbH	Réseau de surveillance médical
US9295417B2 (en)	2011-04-29	2016-03-29	Seventh Sense Biosystems, Inc.	Systems and methods for collecting fluid from a subject
WO2012018486A2 (fr)	2010-07-26	2012-02-09	Seventh Sense Biosystems, Inc.	Distribution et/ou réception rapide de fluides
CN104434136A (zh)	2009-03-02	2015-03-25	第七感生物系统有限公司	用于抽出血液的装置
US9198568B2 (en)	2010-03-04	2015-12-01	The General Hospital Corporation	Methods and systems of matching voice deficits with a tunable mucosal implant to restore and enhance individualized human sound and voice production
US20120006100A1 (en)	2010-07-06	2012-01-12	Medtronic Minimed, Inc.	Method and/or system for determining blood glucose reference sample times
WO2012021801A2 (fr)	2010-08-13	2012-02-16	Seventh Sense Biosystems, Inc.	Systèmes et procédés adaptés pour surveiller des sujets
WO2012064802A1 (fr)	2010-11-09	2012-05-18	Seventh Sense Biosystems, Inc.	Systèmes et interfaces pour prélèvement sanguin
KR102013466B1 (ko)	2011-04-29	2019-08-22	세븐쓰 센스 바이오시스템즈, 인크.	유체들의 전달 및/또는 수용
JP2014516644A (ja)	2011-04-29	2014-07-17	セブンスセンスバイオシステムズ，インコーポレーテッド	血斑または他の体液の収集および／または操作のためのデバイスおよび方法
US20130158468A1 (en)	2011-12-19	2013-06-20	Seventh Sense Biosystems, Inc.	Delivering and/or receiving material with respect to a subject surface
US9968284B2 (en) *	2011-12-02	2018-05-15	Clinitech, Llc	Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device
US10898116B2 (en)	2013-03-15	2021-01-26	Cambridge Medical Technologies LLC	Methods of manufacture to optimize performance of transdermal sampling and analysis device
KR102478639B1 (ko)	2016-02-23	2022-12-19	노을 주식회사	표지 물질을 저장하는 패치, 이를 이용하는 조직 진단 방법 및 장치
KR20170099739A (ko)	2016-02-23	2017-09-01	노을 주식회사	접촉식 염색 보조 패치, 그 제조 방법 및 이를 이용하는 염색 방법
US10371610B2 (en)	2016-02-23	2019-08-06	Noul Co., Ltd.	Contact-type patch, staining method using the same, and manufacturing method thereof
US11375931B2 (en)	2019-08-08	2022-07-05	Cambridge Medical Technologies LLC	Non-invasive transdermal sampling and analysis device incorporating an electrochemical bioassay

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2907342B2 (ja)	1988-01-29	1999-06-21	ザリージェンツオブザユニバーシティーオブカリフォルニア	イオン滲透非侵襲的サンプリングまたは送出装置
US5458140A (en)	1993-11-15	1995-10-17	Non-Invasive Monitoring Company (Nimco)	Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5771890A (en) *	1994-06-24	1998-06-30	Cygnus, Inc.	Device and method for sampling of substances using alternating polarity
US5947921A (en)	1995-12-18	1999-09-07	Massachusetts Institute Of Technology	Chemical and physical enhancers and ultrasound for transdermal drug delivery
US6002961A (en)	1995-07-25	1999-12-14	Massachusetts Institute Of Technology	Transdermal protein delivery using low-frequency sonophoresis
US6689265B2 (en) *	1995-10-11	2004-02-10	Therasense, Inc.	Electrochemical analyte sensors using thermostable soybean peroxidase
US5711861A (en) *	1995-11-22	1998-01-27	Ward; W. Kenneth	Device for monitoring changes in analyte concentration
DE19602861C2 (de) *	1996-01-28	1997-12-11	Meinhard Prof Dr Knoll	Probenahmesystem für in Trägerflüssigkeiten enthaltene Analyte sowie Verfahren zu seiner Herstellung
US6009343A (en)	1996-02-23	1999-12-28	Abbott Laboratories	Enhanced transdermal transport of fluid using vacuum
US7105352B2 (en) *	1996-11-06	2006-09-12	University Of Pittsburgh	Intelligent polymerized crystalline colloidal array carbohydrate sensors
US6117643A (en) *	1997-11-25	2000-09-12	Ut Battelle, Llc	Bioluminescent bioreporter integrated circuit
US6579690B1 (en) *	1997-12-05	2003-06-17	Therasense, Inc.	Blood analyte monitoring through subcutaneous measurement
US20060015058A1 (en) *	1998-01-08	2006-01-19	Kellogg Scott C	Agents and methods for enhancement of transdermal transport
US7066884B2 (en)	1998-01-08	2006-06-27	Sontra Medical, Inc.	System, method, and device for non-invasive body fluid sampling and analysis
US6190315B1 (en) *	1998-01-08	2001-02-20	Sontra Medical, Inc.	Sonophoretic enhanced transdermal transport
CA2265119C (fr) *	1998-03-13	2002-12-03	Cygnus, Inc.	Biocapteur et systeme d'echantillonnage iontophoresique et methodes d'utilisation de ceux-ci
DE69914319T2 (de) *	1998-05-13	2004-11-18	Cygnus, Inc., Redwood City	Signalverarbeitung zur messung von physiologischen analyten
US20040171980A1 (en) *	1998-12-18	2004-09-02	Sontra Medical, Inc.	Method and apparatus for enhancement of transdermal transport
EP1064046A1 (fr) *	1999-04-22	2001-01-03	Cygnus, Inc.	Procedes et dispositifs pour enlever les especes interferentes
US7181261B2 (en) *	2000-05-15	2007-02-20	Silver James H	Implantable, retrievable, thrombus minimizing sensors
US6837988B2 (en)	2001-06-12	2005-01-04	Lifescan, Inc.	Biological fluid sampling and analyte measurement devices and methods
WO2003089506A1 (fr) *	2002-04-22	2003-10-30	Purdue Research Foundation	Hydrogels presentant des proprietes d'elasticite et de resistance mecanique ameliorees
US7150975B2 (en) *	2002-08-19	2006-12-19	Animas Technologies, Llc	Hydrogel composition for measuring glucose flux
US6931327B2 (en) *	2003-08-01	2005-08-16	Dexcom, Inc.	System and methods for processing analyte sensor data

2005
- 2005-10-27 WO PCT/US2005/038785 patent/WO2006050032A2/fr not_active Ceased
- 2005-10-27 CA CA2584699A patent/CA2584699C/fr not_active Expired - Fee Related
- 2005-10-27 AU AU2005302584A patent/AU2005302584B2/en not_active Ceased
- 2005-10-27 EP EP05824881A patent/EP1819283A4/fr active Pending
- 2005-10-27 WO PCT/US2005/038784 patent/WO2006050031A2/fr not_active Ceased
- 2005-10-27 WO PCT/US2005/038786 patent/WO2006050033A2/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2006050031A9 (fr)	2006-06-15
WO2006050033B1 (fr)	2006-12-14
WO2006050032A2 (fr)	2006-05-11
AU2005302584A1 (en)	2006-05-11
EP1819283A4 (fr)	2011-08-10
WO2006050032A9 (fr)	2006-11-02
WO2006050033A3 (fr)	2006-11-02
WO2006050031A2 (fr)	2006-05-11
WO2006050033A2 (fr)	2006-05-11
WO2006050033A9 (fr)	2007-02-01
CA2584699A1 (fr)	2006-05-11
EP1819283A2 (fr)	2007-08-22
WO2006050032A3 (fr)	2006-09-08
AU2005302584B2 (en)	2011-08-11
WO2006050031A3 (fr)	2007-05-18

Publication	Publication Date	Title
US8224414B2 (en)	2012-07-17	System and method for analyte sampling and analysis with hydrogel
CA2584699C (fr)	2015-12-08	Systeme et procede d'echantillonnage d'un analyte et analyse avec un hydrogel
CN100574700C (zh)	2009-12-30	使用水凝胶对分析物取样和分析的系统和方法
JP5502279B2 (ja)	2014-05-28	ヒドロゲルを使用した検体のサンプリングおよび分析のためのシステムおよび方法
JP5965364B2 (ja)	2016-08-03	経皮的被検体モニタリングシステム
McGarraugh	2009	The chemistry of commercial continuous glucose monitors
US7066884B2 (en)	2006-06-27	System, method, and device for non-invasive body fluid sampling and analysis
CA2374751C (fr)	2009-10-13	Systeme, procede et dispositif pour le prelevement non-invasif et l'analyse de fluides organiques
US20180242913A1 (en)	2018-08-30	Method Of Making A Multi-Layer Pad For Use In Determining An Analyte Concentration
HK1143052B (en)	2015-02-18	Transdermal analyte monitoring systems and methods for analyte detection
HK1143052A (en)	2010-12-24	Transdermal analyte monitoring systems and methods for analyte detection

Legal Events

Date	Code	Title	Description
2010-09-17	EEER	Examination request
2018-12-10	MKLA	Lapsed	Effective date: 20181029